{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["diabetes", "diabetic complication", "ginsenoside Rb1", "multi-target effects"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30823412", "DateCompleted": {"Year": "2019", "Month": "12", "Day": "02"}, "DateRevised": {"Year": "2020", "Month": "03", "Day": "09"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "02", "Day": "28"}], "Language": ["eng"], "ELocationID": ["204", "10.3390/cells8030204"], "Journal": {"ISSN": "2073-4409", "JournalIssue": {"Volume": "8", "Issue": "3", "PubDate": {"Year": "2019", "Month": "Feb", "Day": "28"}}, "Title": "Cells", "ISOAbbreviation": "Cells"}, "ArticleTitle": "Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis.", "Abstract": {"AbstractText": ["<i>Panax ginseng</i> and <i>Panax notoginseng</i>, two well-known medical plants with economic value, have a long history of use for managing various diseases in Asian countries. Accumulating clinical and experimental evidence suggests that notoginsenosides and ginsenosides, which are the major bioactive components of the plants, have a variety of beneficial effects on several types of disease, including metabolic, vascular, and central nervous system disease. Considerable attention has been focused on ginsenoside Rb1 derived from their common ownership as an anti-diabetic agent that can attenuate insulin resistance and various complications. Particularly, in vitro and in vivo models have suggested that ginsenoside Rb1 exerts various pharmacological effects on metabolic disorders, including attenuation of glycemia, hypertension, and hyperlipidemia, which depend on the modulation of oxidative stress, inflammatory response, autophagy, and anti-apoptosis effects. Regulation of these pathophysiological mechanisms can improve blood glucose and insulin resistance and protect against macrovascular/microvascular related complications. This review summarizes the pharmacological effects and mechanisms of action of ginsenoside Rb1 in the management of diabetes or diabetic complications. Moreover, a multi-target effect and mechanism analysis of its antidiabetic actions were performed to provide a theoretical basis for further pharmacological studies and new drug development for clinical treatment of type 2 diabetes. In conclusion, ginsenoside Rb1 exerts significant anti-obesity, anti-hyperglycemic, and anti-diabetic effects by regulating the effects of glycolipid metabolism and improving insulin and leptin sensitivities. All of these findings suggest ginsenoside Rb1 exerts protective effects on diabetes and diabetic complications by the regulation of mitochondrial energy metabolism, improving insulin resistance and alleviating the occurrence complications, which should be further explored. Hence, ginsenoside Rb1 may be developed as a potential anti-obesity, anti-hyperglycemic, and anti-diabetic agent with multi-target effects."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. zhoup0520@163.com."}, {"Identifier": [], "Affiliation": "Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. zhoup0520@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China. zhoup0520@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing 100193, China. zhoup0520@163.com."}], "LastName": "Zhou", "ForeName": "Ping", "Initials": "P"}, {"Identifier": ["0000-0002-5062-7843"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. ginseng123@163.com."}, {"Identifier": [], "Affiliation": "Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. ginseng123@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China. ginseng123@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing 100193, China. ginseng123@163.com."}], "LastName": "Xie", "ForeName": "Weijie", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. wym91116@163.com."}, {"Identifier": [], "Affiliation": "Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. wym91116@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China. wym91116@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing 100193, China. wym91116@163.com."}], "LastName": "He", "ForeName": "Shuaibing", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing 100020, China. sun.yifan@imicams.ac.cn."}], "LastName": "Sun", "ForeName": "Yifan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. xbmeng@implad.ac.cn."}, {"Identifier": [], "Affiliation": "Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. xbmeng@implad.ac.cn."}, {"Identifier": [], "Affiliation": "Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China. xbmeng@implad.ac.cn."}, {"Identifier": [], "Affiliation": "Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing 100193, China. xbmeng@implad.ac.cn."}], "LastName": "Meng", "ForeName": "Xiangbao", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. sunguibopaper@163.com."}, {"Identifier": [], "Affiliation": "Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. sunguibopaper@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China. sunguibopaper@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing 100193, China. sunguibopaper@163.com."}], "LastName": "Sun", "ForeName": "Guibo", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. sunxiaobo@163.com."}, {"Identifier": [], "Affiliation": "Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. sunxiaobo@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China. sunxiaobo@163.com."}, {"Identifier": [], "Affiliation": "Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing 100193, China. sunxiaobo@163.com."}], "LastName": "Sun", "ForeName": "Xiaobo", "Initials": "X"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Cells", "NlmUniqueID": "101600052", "ISSNLinking": "2073-4409"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Ginsenosides"}, {"RegistryNumber": "0", "NameOfSubstance": "Hypoglycemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protective Agents"}, {"RegistryNumber": "7413S0WMH6", "NameOfSubstance": "ginsenoside Rb1"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug therapy", "genetics"], "DescriptorName": "Diabetes Complications"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gastrointestinal Microbiome"}, {"QualifierName": [], "DescriptorName": "Gene Regulatory Networks"}, {"QualifierName": ["chemistry", "pharmacology", "therapeutic use"], "DescriptorName": "Ginsenosides"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry", "pharmacology", "therapeutic use"], "DescriptorName": "Hypoglycemic Agents"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Protective Agents"}], "CoiStatement": "The authors declare they have no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Muoio D.M., Newgard C.B. Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008;9:193\u2013205. doi: 10.1038/nrm2327.", "ArticleIdList": ["10.1038/nrm2327", "18200017"]}, {"Citation": "Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840. doi: 10.1038/nature05482.", "ArticleIdList": ["10.1038/nature05482", "17167471"]}, {"Citation": "Venables M.C., Jeukendrup A.E. Physical inactivity and obesity: Links with insulin resistance and type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 2010;25:S18\u2013S23. doi: 10.1002/dmrr.983.", "ArticleIdList": ["10.1002/dmrr.983", "19662619"]}, {"Citation": "Romero-Aroca P., Mendez-Marin I., Baget-Bernaldiz M., Fern\u00e9ndez-Ballart J., Santos-Blanco E. Review of the relationship between renal and retinal microangiopathy in diabetes mellitus patients. Curr. Diabetes Rev. 2010;6:88\u2013101. doi: 10.2174/157339910790909387.", "ArticleIdList": ["10.2174/157339910790909387", "20034365"]}, {"Citation": "Ferrannini E., Natali A., Camastra S., Nannipieri M., Mari A., Adam K.P., Milburn M.V., Kastenm\u00fcller G., Adamski J., Tuomi T. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes. 2013;62:1730\u20131737. doi: 10.2337/db12-0707.", "ArticleIdList": ["10.2337/db12-0707", "PMC3636608", "23160532"]}, {"Citation": "Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813\u2013820. doi: 10.1038/414813a.", "ArticleIdList": ["10.1038/414813a", "11742414"]}, {"Citation": "Setter S.M., Iltz J.L., Thams J., Campbell R.K. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy. Clin. Ther. 2003;25:2991\u20133026. doi: 10.1016/S0149-2918(03)90089-0.", "ArticleIdList": ["10.1016/S0149-2918(03)90089-0", "14749143"]}, {"Citation": "Nanjan M.J., Mohammed M., Prashantha Kumar B.R., Chandrasekar M.J.N. Thiazolidinediones as antidiabetic agents: A critical review. Bioorganic Chem. 2018;77:548\u2013567. doi: 10.1016/j.bioorg.2018.02.009.", "ArticleIdList": ["10.1016/j.bioorg.2018.02.009", "29475164"]}, {"Citation": "Oikonomou E., Mourouzis K., Fountoulakis P., Papamikroulis G.A., Siasos G., Antonopoulos A., Vogiatzi G., Tsalamadris S., Vavuranakis M., Tousoulis D. Interrelationship between diabetes mellitus and heart failure: The role of peroxisome proliferator-activated receptors in left ventricle performance. Heart Fail. Rev. 2018;23:389\u2013408. doi: 10.1007/s10741-018-9682-3.", "ArticleIdList": ["10.1007/s10741-018-9682-3", "29453696"]}, {"Citation": "Thangavel N., Al Bratty M., Akhtar Javed S., Ahsan W., Alhazmi H.A. Targeting peroxisome proliferator-activated receptors using thiazolidinediones: Strategy for design of novel antidiabetic drugs. Int. J. Med. Chem. 2017;2017:1069718. doi: 10.1155/2017/1069718.", "ArticleIdList": ["10.1155/2017/1069718", "PMC5474549", "28656106"]}, {"Citation": "Glosse P., Foller M. AMP-Activated protein kinase (AMPK)-dependent regulation of renal transport. Int. J. Mol. Sci. 2018;19:3481. doi: 10.3390/ijms19113481.", "ArticleIdList": ["10.3390/ijms19113481", "PMC6274953", "30404151"]}, {"Citation": "Rozanska D., Regulska-Ilow B. The significance of anthocyanins in the prevention and treatment of type 2 diabetes. Adv. Clin. Exp. Med. 2018;27:135\u2013142. doi: 10.17219/acem/64983.", "ArticleIdList": ["10.17219/acem/64983", "29521054"]}, {"Citation": "Wang Q., Liu S., Zhai A., Zhang B., Tian G. AMPK-mediated regulation of lipid metabolism by phosphorylation. Biol. Pharm. Bull. 2018;41:985\u2013993. doi: 10.1248/bpb.b17-00724.", "ArticleIdList": ["10.1248/bpb.b17-00724", "29709897"]}, {"Citation": "Garcia-Galiano D., Borges B.C., Allen S.J., Elias C.F. PI3K signaling in leptin receptor cells: Role in growth and reproduction. J. Neuroendocrinol. 2019 doi: 10.1111/jne.12685.", "ArticleIdList": ["10.1111/jne.12685", "PMC6533139", "30618188"]}, {"Citation": "John C.M., Mohamed Yusof N.I.S., Abdul Aziz S.H., Mohd Fauzi F. Maternal cognitive impairment associated with gestational diabetes mellitus\u2014A review of potential contributing mechanisms. Int. J. Mol. Sci. 2018;19:3894. doi: 10.3390/ijms19123894.", "ArticleIdList": ["10.3390/ijms19123894", "PMC6321050", "30563117"]}, {"Citation": "Mabhida S.E., Dludla P.V., Johnson R., Ndlovu M., Louw J., Opoku A.R., Mosa R.A. Protective effect of triterpenes against diabetes-induced beta-cell damage: An overview of in vitro and in vivo studies. Pharm. Res. 2018;137:179\u2013192. doi: 10.1016/j.phrs.2018.10.004.", "ArticleIdList": ["10.1016/j.phrs.2018.10.004", "30315968"]}, {"Citation": "Ferguson R.D., Gallagher E.J., Scheinman E.J., Damouni R., LeRoith D. The Epidemiology and Molecular Mechanisms Linking Obesity, Diabetes, and Cancer. Vitam. Horm. 2013;93:51\u201398.", "ArticleIdList": ["23810003"]}, {"Citation": "Hirosumi J., Tuncman G., Chang L., G\u00f6rg\u00fcn C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333\u2013336. doi: 10.1038/nature01137.", "ArticleIdList": ["10.1038/nature01137", "12447443"]}, {"Citation": "Sheetz M.J., King G.L. Molecular understanding of hyperglycemia\u2019s adverse effects for diabetic complications. JAMA. 2002;288:2579\u20132588. doi: 10.1001/jama.288.20.2579.", "ArticleIdList": ["10.1001/jama.288.20.2579", "12444865"]}, {"Citation": "Hunt J.V., Wolff S.P. Oxidative glycation and free radical production: A causal mechanism of diabetic complications. Free Radic. Res. Commun. 1990;12:115\u2013123. doi: 10.3109/10715769109145775.", "ArticleIdList": ["10.3109/10715769109145775", "1649079"]}, {"Citation": "Ishii H., Hayashino Y., Akai Y., Yabuta M., Tsujii S. Dipeptidyl peptidase\u20144 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study) J. Diabetes Investig. 2018;9:137\u2013145. doi: 10.1111/jdi.12659.", "ArticleIdList": ["10.1111/jdi.12659", "PMC5754532", "28296349"]}, {"Citation": "Choi K., Kim Y.B. Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J. Intern. Med. 2010;25:119\u2013129. doi: 10.3904/kjim.2010.25.2.119.", "ArticleIdList": ["10.3904/kjim.2010.25.2.119", "PMC2880683", "20526383"]}, {"Citation": "Zhou J., Huang K., Lei X.G. Selenium and diabetes-evidence from animal studies. Free Radic. Biol. Med. 2013;65:1548\u20131556. doi: 10.1016/j.freeradbiomed.2013.07.012.", "ArticleIdList": ["10.1016/j.freeradbiomed.2013.07.012", "PMC3859733", "23867154"]}, {"Citation": "Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., Tataranni P.A. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001;86:1930\u20131935. doi: 10.1210/jcem.86.5.7463.", "ArticleIdList": ["10.1210/jcem.86.5.7463", "11344187"]}, {"Citation": "Dios S.T.D., Frontanilla K.V., Nigro J., Ballinger M.L., Ivey M.E., Cawson E.A., Little P.J. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J. Diabetes Its Complicat. 2007;21:108\u2013117. doi: 10.1016/j.jdiacomp.2006.03.003.", "ArticleIdList": ["10.1016/j.jdiacomp.2006.03.003", "17331859"]}, {"Citation": "Bekele B.B. The prevalence of macro and microvascular complications of DM among patients in Ethiopia 1990-2017: Systematic review. Diabetes Metab. Syndr. 2019;13:672\u2013677. doi: 10.1016/j.dsx.2018.11.046.", "ArticleIdList": ["10.1016/j.dsx.2018.11.046", "30641787"]}, {"Citation": "Feng Y., Fang Y., Wang Y., Hao Y. Acupoint therapy on diabetes mellitus and its common chronic complications: A review of its mechanisms. Biomed. Res. Int. 2018;2018:3128378. doi: 10.1155/2018/3128378.", "ArticleIdList": ["10.1155/2018/3128378", "PMC6217896", "30426006"]}, {"Citation": "Lao Y., Wang X., Xu N., Zhang H., Xu H. Application of proteomics to determine the mechanism of action of traditional Chinese medicine remedies. J. Ethnopharmacol. 2014;155:1\u20138. doi: 10.1016/j.jep.2014.05.022.", "ArticleIdList": ["10.1016/j.jep.2014.05.022", "24862488"]}, {"Citation": "Sharma B.R., Gautam L.N., Adhikari D., Karki R. A comprehensive review on chemical profiling of nelumbo nucifera: potential for drug development. Phytother. Res. 2017;31:3\u201326. doi: 10.1002/ptr.5732.", "ArticleIdList": ["10.1002/ptr.5732", "27667670"]}, {"Citation": "Sun G.D., Li C.Y., Cui W.P., Guo Q.Y., Dong C.Q., Zou H.B., Liu S.J., Dong W.P., Miao L.N. Review of herbal traditional chinese medicine for the treatment of diabetic nephropathy. J. Diabetes Res. 2016;2016:5749857. doi: 10.1155/2016/5749857.", "ArticleIdList": ["10.1155/2016/5749857", "PMC4662991", "26649322"]}, {"Citation": "Zhang T.T., Jiang J.G. Active ingredients of traditional Chinese medicine in the treatment of diabetes and diabetic complications. Expert Opin. Investig. Drugs. 2012;21:1625\u20131642. doi: 10.1517/13543784.2012.713937.", "ArticleIdList": ["10.1517/13543784.2012.713937", "22862558"]}, {"Citation": "Zhou X., Chen L.-L., Xie R.F., Lam W., Zhang Z.-J., Jiang Z.-L., Cheng Y.-C. Chemosynthesis pathway and bioactivities comparison of saponins in radix and flower of Panax notoginseng (Burk.) F.H. Chen. J. Ethnopharmacol. 2017;201:56\u201372. doi: 10.1016/j.jep.2016.11.008.", "ArticleIdList": ["10.1016/j.jep.2016.11.008", "27838357"]}, {"Citation": "Kim J.H. Pharmacological and medical applications of Panax ginseng and ginsenosides: A review for use in cardiovascular diseases. J. Ginseng Res. 2018;42:264\u2013269. doi: 10.1016/j.jgr.2017.10.004.", "ArticleIdList": ["10.1016/j.jgr.2017.10.004", "PMC6026386", "29983607"]}, {"Citation": "Su P., Wang L., Du S.J., Xin W.F., Zhang W.S. Advance in studies of Panax notoginseng saponins on pharmacological mechanism of nervous system disease. China J. Chin. Mater. Med. 2014;39:4516\u20134521. (In Chinese)", "ArticleIdList": ["25911793"]}, {"Citation": "Mancuso C., Santangelo R. Panax ginseng and Panax quinquefolius: From pharmacology to toxicology. Food Chem. Toxicol. 2017;107:362\u2013372. doi: 10.1016/j.fct.2017.07.019.", "ArticleIdList": ["10.1016/j.fct.2017.07.019", "PMC7116968", "28698154"]}, {"Citation": "Behl T., Kotwani A. Chinese herbal drugs for the treatment of diabetic retinopathy. J. Pharm. Pharmacol. 2017;69:223\u2013235. doi: 10.1111/jphp.12683.", "ArticleIdList": ["10.1111/jphp.12683", "28124440"]}, {"Citation": "Chen Z.H., Li J., Liu J., Zhao Y., Zhang P., Zhang M.X., Zhang L. Saponins isolated from the root of Panax notoginseng showed significant anti-diabetic effects in KK-Ay mice. Am. J. Chin. Med. 2008;36:939\u2013951. doi: 10.1142/S0192415X08006363.", "ArticleIdList": ["10.1142/S0192415X08006363", "19051359"]}, {"Citation": "Du Y.G., Wang L.P., Qian J.W., Zhang K.N., Chai K.F. Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats. Chin. J. Integr. Med. 2016;22:910\u2013917. doi: 10.1007/s11655-015-2446-1.", "ArticleIdList": ["10.1007/s11655-015-2446-1", "26712211"]}, {"Citation": "Allison D.J., Ditor D.S. The common inflammatory etiology of depression and cognitive impairment: A therapeutic target. J. Neuroinflamm. 2014;11:151. doi: 10.1186/s12974-014-0151-1.", "ArticleIdList": ["10.1186/s12974-014-0151-1", "PMC4156619", "25178630"]}, {"Citation": "Jeon S.W., Kim Y.K. Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness? World J. Psychiatry. 2016;6:283\u2013293. doi: 10.5498/wjp.v6.i3.283.", "ArticleIdList": ["10.5498/wjp.v6.i3.283", "PMC5031928", "27679767"]}, {"Citation": "Zhang J., Ding L., Wang B., Ren G., Sun A., Deng C., Wei X., Mani S., Wang Z., Dou W. Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. J. Pharmacol. Exp. Ther. 2015;352:315\u2013324. doi: 10.1124/jpet.114.218750.", "ArticleIdList": ["10.1124/jpet.114.218750", "PMC4293438", "25472953"]}, {"Citation": "Zheng X., Liang Y., Kang A., Ma S.J., Xing L., Zhou Y.Y., Dai C., Xie H., Xie L., Wang G.J., et al. Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats. Neuroscience. 2014;256:210\u2013222. doi: 10.1016/j.neuroscience.2013.10.023.", "ArticleIdList": ["10.1016/j.neuroscience.2013.10.023", "24161284"]}, {"Citation": "Xie T., Zhou X.P., Lin L.L., Xu J.Y., Shen C.S., Feng Z., Zhou L.L., Shan J.J. Metabolomics analysis of Tripterygium wilfordii formulation based on theory of detoxicity compatibility. China J. Chin. Mater. Med. 2016;41:1124\u20131129. doi: 10.4268/cjcmm20160625. (In Chinese)", "ArticleIdList": ["10.4268/cjcmm20160625", "28875681"]}, {"Citation": "Zhang H., Li Z., Zhou Z., Yang H., Zhong Z., Lou C. Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20(S)-protopanaxadiol in mice models of despair. Pharmacol. Biochem. Behav. 2016;140:17\u201326. doi: 10.1016/j.pbb.2015.10.018.", "ArticleIdList": ["10.1016/j.pbb.2015.10.018", "26528894"]}, {"Citation": "Pang H.H., Li M.Y., Wang Y., Tang M.K., Ma C.H., Huang J.M. Effect of compatible herbs on the pharmacokinetics of effective components of Panax notoginseng in Fufang Xueshuantong Capsule. J. Zhejiang Univ. Sci. B. 2017;18:343\u2013352. doi: 10.1631/jzus.B1600235.", "ArticleIdList": ["10.1631/jzus.B1600235", "PMC5394099", "28378572"]}, {"Citation": "Tian Z., Pang H., Du S., Lu Y., Zhang L., Wu H., Guo S., Wang M., Zhang Q. Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats. J. Chromatogr. B. 2017;1040:136\u2013143. doi: 10.1016/j.jchromb.2016.12.007.", "ArticleIdList": ["10.1016/j.jchromb.2016.12.007", "27978468"]}, {"Citation": "Zhao S., Zheng M.X., Chen H.E., Wu C.Y., Wang W.T. Effect of panax notoginseng saponins injection on the p38MAPK pathway in lung tissue in a rat model of hypoxic pulmonary hypertension. Chin. J. Integr. Med. 2015;21:147\u2013151. doi: 10.1007/s11655-014-1790-2.", "ArticleIdList": ["10.1007/s11655-014-1790-2", "25523598"]}, {"Citation": "Zhai Y., Meng X., Luo Y., Wu Y., Ye T., Zhou P., Ding S., Wang M., Lu S., Zhu L. Notoginsenoside R1 ameliorates diabetic encephalopathy by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Oncotarget. 2018;9:9344\u20139363. doi: 10.18632/oncotarget.24295.", "ArticleIdList": ["10.18632/oncotarget.24295", "PMC5823646", "29507694"]}, {"Citation": "Hou Q.L., Wang Y., Li Y.B., Hu X.L., Wang S.L. Protective effect of notoginsenoside R1 on neuron injury induced by OGD/R through ATF6/Akt signaling pathway. China J. Chin. Mater. Med. 2017;42:1167\u20131174. (In Chinese)", "ArticleIdList": ["29027434"]}, {"Citation": "Li W., Ling S., Yang Y., Hu Z., Davies H., Fang M. Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments. Neuro Endocrinol. Lett. 2014;35:104\u2013109.", "ArticleIdList": ["24878979"]}, {"Citation": "Yang X., Yang S., Hong C., Yu W., Guonian W. Panax Notoginseng Saponins attenuates sevofluraneinduced nerve cell injury by modulating AKT signaling pathway. Mol. Med. Rep. 2017;16:7829\u20137834. doi: 10.3892/mmr.2017.7519.", "ArticleIdList": ["10.3892/mmr.2017.7519", "28944861"]}, {"Citation": "Wang T., Guo R., Zhou G., Zhou X., Kou Z., Sui F., Li C., Tang L., Wang Z. Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) F.H. Chen: A review. J. Ethnopharmacol. 2016;188:234\u2013258. doi: 10.1016/j.jep.2016.05.005.", "ArticleIdList": ["10.1016/j.jep.2016.05.005", "27154405"]}, {"Citation": "Berge L.I., Riise T. Comorbidity between Type 2 diabetes and depression in the adult population: Directions of the association and its possible pathophysiological mechanisms. Int. J. Endocrinol. 2015;2015:164760. doi: 10.1155/2015/164760.", "ArticleIdList": ["10.1155/2015/164760", "PMC4589629", "26457080"]}, {"Citation": "Xie W., Meng X., Zhai Y., Zhou P., Ye T., Wang Z., Sun G., Sun X. Panax notoginseng saponins: A review of its mechanisms of antidepressant or anxiolytic effects and network analysis on phytochemistry and pharmacology. Molecules. 2018;23:940. doi: 10.3390/molecules23040940.", "ArticleIdList": ["10.3390/molecules23040940", "PMC6017639", "29673237"]}, {"Citation": "Xie W., Zhou P., Sun Y., Meng X., Dai Z., Sun G., Sun X. Protective effects and target network analysis of ginsenoside Rg1 in cerebral ischemia and reperfusion injury: A comprehensive overview of experimental studies. Cells. 2018;7:270. doi: 10.3390/cells7120270.", "ArticleIdList": ["10.3390/cells7120270", "PMC6316103", "30545139"]}, {"Citation": "Chen C.F., Chiou W.F., Zhang J.T. Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium. Acta Pharmacol. Sin. 2008;29:1103\u20131108. doi: 10.1111/j.1745-7254.2008.00868.x.", "ArticleIdList": ["10.1111/j.1745-7254.2008.00868.x", "18718179"]}, {"Citation": "Chen F., Wen Q., Jiang J., Li H.L., Tan Y.F., Li Y.H., Zeng N.K. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? J. Ethnopharmacol. 2016;179:253\u2013264. doi: 10.1016/j.jep.2015.12.031.", "ArticleIdList": ["10.1016/j.jep.2015.12.031", "26723469"]}, {"Citation": "Li S., Tang Y., Liu C., Zhang Y. Development of a method to screen and isolate potential alpha-glucosidase inhibitors from Panax japonicus CA Meyer by ultrafiltration, liquid chromatography, and counter-current chromatography. J. Sep. Sci. 2015;38:2014\u20132023. doi: 10.1002/jssc.201500064.", "ArticleIdList": ["10.1002/jssc.201500064", "25847676"]}, {"Citation": "Li X., Wu L., Fan X., Zhang B., Gao X., Wang Y., Cheng Y. Network pharmacology study on major active compounds of Fufang Danshen formula. China J. Chin. Mater. Med. 2011;36:2911\u20132915. (In Chinese)", "ArticleIdList": ["22308672"]}, {"Citation": "Park M.J., Bae C.S., Lim S.K., Kim D.I., Lim J.C., Kim J.C., Han H.J., Moon J.H., Kim K.Y., Yoon K.C., et al. Effect of protopanaxadiol derivatives in high glucose-induced fibronectin expression in primary cultured rat mesangial cells: Role of mitogen-activated protein kinases and Akt. Arch. Pharmacal. Res. 2010;33:151\u2013157. doi: 10.1007/s12272-010-2237-3.", "ArticleIdList": ["10.1007/s12272-010-2237-3", "20191356"]}, {"Citation": "Tabandeh M.R., Jafari H., Hosseini S.A., Hashemitabar M. Ginsenoside Rb1 stimulates adiponectin signaling in C2C12 muscle cells through up-regulation of AdipoR1 and AdipoR2 proteins. Pharm. Biol. 2015;53:125\u2013132. doi: 10.3109/13880209.2014.912237.", "ArticleIdList": ["10.3109/13880209.2014.912237", "25311947"]}, {"Citation": "Wu Y., Yu Y., Szabo A., Han M., Huang X.F. Central inflammation and leptin resistance are attenuated by ginsenoside Rb1 treatment in obese mice fed a high-fat diet. PLoS ONE. 2014;9:e92618. doi: 10.1371/journal.pone.0092618.", "ArticleIdList": ["10.1371/journal.pone.0092618", "PMC3968027", "24675731"]}, {"Citation": "Xue B., Sun L., Li X., Wang X., Zhang Y., Mu Y., Liang L. Ginsenoside Rb1 relieves glucose fluctuation-induced oxidative stress and apoptosis in Schwann cells. Neural Regen. Res. 2012;7:2340\u20132346. doi: 10.3969/j.issn.1673-5374.2012.30.003.", "ArticleIdList": ["10.3969/j.issn.1673-5374.2012.30.003", "PMC4268738", "25538758"]}, {"Citation": "Yu X., Ye L., Zhang H., Zhao J., Wang G., Guo C., Shang W. Ginsenoside Rb1 ameliorates liver fat accumulation by upregulating perilipin expression in adipose tissue of db/db obese mice. J. Ginseng Res. 2015;39:199\u2013205. doi: 10.1016/j.jgr.2014.11.004.", "ArticleIdList": ["10.1016/j.jgr.2014.11.004", "PMC4506369", "26199550"]}, {"Citation": "Sanada S., Kondo N., Shoji J., Tanaka O., Shibata S. Studies on the saponins of ginseng. II. Structures of ginsenoside-Re, -Rf and -Rg2. Chem. Pharm. Bull. 2008;22:2407\u20132412. doi: 10.1248/cpb.22.2407.", "ArticleIdList": ["10.1248/cpb.22.2407"]}, {"Citation": "Chen Q.S. Pharmacological studies on notoginseng saponins isolated from the fibrous root of Panax notoginseng. Zhong Yao Tong Bao. 1987;12:45\u201347.", "ArticleIdList": ["2957098"]}, {"Citation": "Washida D., Kitanaka S. Determination of polyacetylenes and ginsenosides in Panax species using high performance liquid chromatography. Chem. Pharm. Bull. 2003;51:1314\u20131317. doi: 10.1248/cpb.51.1314.", "ArticleIdList": ["10.1248/cpb.51.1314", "14600381"]}, {"Citation": "Nah S.Y., Park H.J., Mccleskey E.W. A trace component of ginseng that inhibits Ca2+ channels through a pertussis toxin-sensitive G protein. Proc. Natl. Acad. Sci. USA. 1995;92:8739\u20138743. doi: 10.1073/pnas.92.19.8739.", "ArticleIdList": ["10.1073/pnas.92.19.8739", "PMC41042", "7568008"]}, {"Citation": "Wang B., Cheng K.K. Hypothalamic AMPK as a Mediator of Hormonal Regulation of Energy Balance. Int. J. Mol. Sci. 2018;19:3552. doi: 10.3390/ijms19113552.", "ArticleIdList": ["10.3390/ijms19113552", "PMC6274700", "30423881"]}, {"Citation": "Lyons C.L., Roche H.M. Nutritional Modulation of AMPK-Impact upon Metabolic-Inflammation. Int. J. Mol. Sci. 2018;19:3092. doi: 10.3390/ijms19103092.", "ArticleIdList": ["10.3390/ijms19103092", "PMC6213547", "30304866"]}, {"Citation": "Xiong Y., Shen L., Liu K.J., Tso P., Xiong Y., Wang G., Woods S.C., Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats. Diabetes. 2010;59:2505\u20132512. doi: 10.2337/db10-0315.", "ArticleIdList": ["10.2337/db10-0315", "PMC3279544", "20682695"]}, {"Citation": "Waki I., Kyo H., Yasuda M., Kimura M. Effects of a hypoglycemic component of ginseng radix on insulin biosynthesis in normal and diabetic animals. J. Pharm. Dyn. 1982;5:547\u2013554. doi: 10.1248/bpb1978.5.547.", "ArticleIdList": ["10.1248/bpb1978.5.547", "6759629"]}, {"Citation": "Zhong Z.D., Wang C.M., Wang W., Shen L., Chen Z.H. Major hypoglycemic ingredients of Panax notoginseng saponins for treating diabetes. J. Sichuan Univ. 2014;45:235\u2013239. (In Chinese)", "ArticleIdList": ["24749347"]}, {"Citation": "Shang W., Yang Y., Jiang B., Jin H., Zhou L., Liu S., Chen M. Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARgamma2 and C/EBPalpha gene expression. Life Sci. 2007;80:618\u2013625. doi: 10.1016/j.lfs.2006.10.021.", "ArticleIdList": ["10.1016/j.lfs.2006.10.021", "17129589"]}, {"Citation": "Shang W., Yang Y., Zhou L., Jiang B., Jin H., Chen M. Ginsenoside Rb1 stimulates glucose uptake through insulin-like signaling pathway in 3T3-L1 adipocytes. J. Endocrinol. 2008;198:561\u2013569. doi: 10.1677/JOE-08-0104.", "ArticleIdList": ["10.1677/JOE-08-0104", "18550785"]}, {"Citation": "Li J., Li R., Li N., Zheng F., Dai Y., Ge Y., Yue H., Yu S. Mechanism of antidiabetic and synergistic effects of ginseng polysaccharide and ginsenoside Rb1 on diabetic rat model. J. Pharm. Biomed. Anal. 2018;158:451\u2013460. doi: 10.1016/j.jpba.2018.06.024.", "ArticleIdList": ["10.1016/j.jpba.2018.06.024", "30032757"]}, {"Citation": "Xie Z., Loi Truong T., Zhang P., Xu F., Xu X., Li P. Dan-Qi prescription ameliorates insulin resistance through overall corrective regulation of glucose and fat metabolism. J. Ethnopharmacol. 2015;172:70\u201379. doi: 10.1016/j.jep.2015.05.041.", "ArticleIdList": ["10.1016/j.jep.2015.05.041", "26087232"]}, {"Citation": "Shang W.B., Guo C., Zhao J., Yu X.Z., Zhang H. Ginsenoside Rb1 upregulates expressions of GLUTs to promote glucose consumption in adiopcytes. China J. Chin. Mater. Med. 2014;39:4448\u20134452.", "ArticleIdList": ["25850283"]}, {"Citation": "Song B., Ding L., Zhang H., Chu Y., Chang Z., Yu Y., Guo D., Zhang S., Liu X. Ginsenoside Rb1 increases insulin sensitivity through suppressing 11beta-hydroxysteroid dehydrogenase type I. Am. J. Transl. Res. 2017;9:1049\u20131057.", "ArticleIdList": ["PMC5375997", "28386332"]}, {"Citation": "Sadie-Van Gijsen H. Adipocyte biology: It is time to upgrade to a new model. J. Cell. Physiol. 2018;234:2399\u20132425. doi: 10.1002/jcp.27266.", "ArticleIdList": ["10.1002/jcp.27266", "30192004"]}, {"Citation": "Smith C.J., Wejksnora P.J., Warner J.R., Rubin C.S., Rosen O.M. Insulin-stimulated protein phosphorylation in 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. USA. 1979;76:2725\u20132729. doi: 10.1073/pnas.76.6.2725.", "ArticleIdList": ["10.1073/pnas.76.6.2725", "PMC383681", "313567"]}, {"Citation": "Shen L., Haas M., Wang D.Q., May A., Lo C.C., Obici S., Tso P., Woods S.C., Liu M. Ginsenoside Rb1 increases insulin sensitivity by activating AMP-activated protein kinase in male rats. Physiol. Rep. 2015;3:e12543. doi: 10.14814/phy2.12543.", "ArticleIdList": ["10.14814/phy2.12543", "PMC4600387", "26359241"]}, {"Citation": "Shen L., Xiong Y., Wang D.Q., Howles P., Basford J.E., Wang J., Xiong Y.Q., Hui D.Y., Woods S.C., Liu M. Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats. J. Lipid Res. 2013;54:1430\u20131438. doi: 10.1194/jlr.M035907.", "ArticleIdList": ["10.1194/jlr.M035907", "PMC3622335", "23434611"]}, {"Citation": "Chen F., Chen Y., Kang X., Zhou Z., Zhang Z., Liu D. Anti-apoptotic function and mechanism of ginseng saponins in Rattus pancreatic beta-cells. Biol. Pharm. Bull. 2012;35:1568\u20131573. doi: 10.1248/bpb.b12-00461.", "ArticleIdList": ["10.1248/bpb.b12-00461", "22975510"]}, {"Citation": "Shen N., Li X., Zhou T., Bilal M.U., Du N., Hu Y., Qin W., Xie Y., Wang H., Wu J., et al. Shensong Yangxin Capsule prevents diabetic myocardial fibrosis by inhibiting TGF-beta1/Smad signaling. J. Ethnopharmacol. 2014;157:161\u2013170. doi: 10.1016/j.jep.2014.09.035.", "ArticleIdList": ["10.1016/j.jep.2014.09.035", "25267579"]}, {"Citation": "Liu C., Zhang M., Hu M.Y., Guo H.F., Li J., Yu Y.L., Jin S., Wang X.T., Liu L., Liu X.D. Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J. Endocrinol. 2013;217:185\u2013196. doi: 10.1530/JOE-12-0502.", "ArticleIdList": ["10.1530/JOE-12-0502", "23444389"]}, {"Citation": "DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 1999;131:281\u2013303. doi: 10.7326/0003-4819-131-4-199908170-00008.", "ArticleIdList": ["10.7326/0003-4819-131-4-199908170-00008", "10454950"]}, {"Citation": "Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005\u20132012. doi: 10.1001/jama.281.21.2005.", "ArticleIdList": ["10.1001/jama.281.21.2005", "10359389"]}, {"Citation": "Cushman W.C., Evans G.W., Byington R.P., Goff D.C., Grimm R.H., Cutler J.A., Simons-Morton D.G., Basile J.N., Corson M.A., Probstfield J.L. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 2010;362:1575\u20131585.", "ArticleIdList": ["PMC4123215", "20228401"]}, {"Citation": "Uzayisenga R., Ayeka P.A., Wang Y. Anti-diabetic potential of Panax notoginseng saponins (PNS): A review. Phytother. Res. 2014;28:510\u2013516. doi: 10.1002/ptr.5026.", "ArticleIdList": ["10.1002/ptr.5026", "23846979"]}, {"Citation": "Bloomgarden Z.T. Diabetes Complications. Diabetes Care. 2004;27:1506. doi: 10.2337/diacare.27.6.1506.", "ArticleIdList": ["10.2337/diacare.27.6.1506", "15161810"]}, {"Citation": "Jiping L., Shuyuan W., Liang F., Dongying M., Qiang F., Yu S., Xiaobin J., Shiping M. Hypoglycemic and antioxidant activities of paeonol and its beneficial effect on diabetic encephalopathy in streptozotocin-induced diabetic rats. J. Med. Food. 2013;16:577\u2013586.", "ArticleIdList": ["23875897"]}, {"Citation": "Sima A.A., Zhang W., Kreipke C.W., Rafols J.A., Hoffman W.H. Inflammation in Diabetic Encephalopathy is Prevented by C-Peptide. Rev. Diabet. Stud. 2009;6:37\u201342. doi: 10.1900/RDS.2009.6.37.", "ArticleIdList": ["10.1900/RDS.2009.6.37", "PMC2712918", "19557294"]}, {"Citation": "Ahmad F.K., Zhiheng H., King G.L. Molecular targets of diabetic cardiovascular complications. Curr. Drug Targets. 2005;6:487\u2013494. doi: 10.2174/1389450054021990.", "ArticleIdList": ["10.2174/1389450054021990", "16026267"]}, {"Citation": "Desmond J., Hirofumi H., Griendling K.K. Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 2006;40:183\u2013192.", "ArticleIdList": ["16413400"]}, {"Citation": "Lu J.M., Weakley S.M., Yang Z., Hu M., Yao Q., Chen C. Ginsenoside Rb1 directly scavenges hydroxyl radical and hypochlorous acid. Curr. Pharm. Des. 2012;18:6339\u20136347. doi: 10.2174/138161212803832254.", "ArticleIdList": ["10.2174/138161212803832254", "22974003"]}, {"Citation": "Zhu J., Wang K.Z., Chu C.T. After the banquet: Mitochondrial biogenesis, mitophagy, and cell survival. Autophagy. 2013;9:1663\u20131676. doi: 10.4161/auto.24135.", "ArticleIdList": ["10.4161/auto.24135", "PMC4028332", "23787782"]}, {"Citation": "Marini M.G., Sonnino C., Previtero M., Biasucci L.M. Targeting inflammation: impact on atherothrombosis. J. Cardiovasc. Transl. Res. 2014;7:9\u201318. doi: 10.1007/s12265-013-9523-7.", "ArticleIdList": ["10.1007/s12265-013-9523-7", "24327329"]}, {"Citation": "Li J., Shao Z.H., Xie J.T., Wang C.Z., Ramachandran S., Yin J.J., Aung H., Li C.Q., Qin G., Vanden Hoek T., et al. The effects of ginsenoside Rb1 on JNK in oxidative injury in cardiomyocytes. Arch. Pharmacal Res. 2012;35:1259\u20131267. doi: 10.1007/s12272-012-0717-3.", "ArticleIdList": ["10.1007/s12272-012-0717-3", "PMC3415887", "22864749"]}, {"Citation": "Chen C., Jiang J., Lu J.M., Chai H., Wang X., Lin P.H., Yao Q. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2010;299:H193\u2013H201. doi: 10.1152/ajpheart.00431.2009.", "ArticleIdList": ["10.1152/ajpheart.00431.2009", "PMC2904138", "20435848"]}, {"Citation": "Hui C., Qiuyan W., Lifeng H., Tian X., Yan F. Ginsenoside Rb1 inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Biol. Pharm. Bull. 2008;31:2050.", "ArticleIdList": ["18981572"]}, {"Citation": "Wang Z., Huang Y., Cheng Y., Tan Y., Wu F., Wu J., Shi H., Zhang H., Yu X., Gao H. Endoplasmic reticulum stress-induced neuronal inflammatory response and apoptosis likely plays a key role in the development of diabetic encephalopathy. Oncotarget. 2016;7:78455\u201378472. doi: 10.18632/oncotarget.12925.", "ArticleIdList": ["10.18632/oncotarget.12925", "PMC5346653", "27793043"]}, {"Citation": "Carlos Alberto Y.W., Helena Maria T.B., Carmen Regla V. GABAergic modulation in diabetic encephalopathy-related depression. Curr. Pharm. Des. 2015;21:4980\u20134988.", "ArticleIdList": ["26365139"]}, {"Citation": "Sang H.L., Jung B.H., Sun Y.K., Lee E.H., Chung B.C. The antistress effect of ginseng total saponin and ginsenoside Rg3 and Rb1 evaluated by brain polyamine level under immobilization stress. Pharmacol. Res. 2006;54:46\u201349.", "ArticleIdList": ["16530422"]}, {"Citation": "Liu D., Zhang H., Gu W., Liu Y., Zhang M. Ginsenoside Rb1 protects hippocampal neurons from high glucose-induced neurotoxicity by inhibiting GSK3beta-mediated CHOP induction. Mol. Med. Rep. 2014;9:1434\u20131438. doi: 10.3892/mmr.2014.1958.", "ArticleIdList": ["10.3892/mmr.2014.1958", "24535619"]}, {"Citation": "Xia R., Zhao B., Wu Y., Hou J.B., Zhang L., Xu J.J., Xia Z.Y. Ginsenoside Rb1 preconditioning enhances eNOS expression and attenuates myocardial ischemia/reperfusion injury in diabetic rats. J. Biomed. Biotechnol. 2011;2011:767930. doi: 10.1155/2011/767930.", "ArticleIdList": ["10.1155/2011/767930", "PMC3196378", "22013385"]}, {"Citation": "Wu Y., Xia Z.Y., Dou J., Zhang L., Xu J.J., Zhao B., Lei S., Liu H.M. Protective effect of ginsenoside Rb1 against myocardial ischemia/reperfusion injury in streptozotocin-induced diabetic rats. Mol. Biol. Rep. 2011;38:4327\u20134335. doi: 10.1007/s11033-010-0558-4.", "ArticleIdList": ["10.1007/s11033-010-0558-4", "21113666"]}, {"Citation": "Liu C., Hu M., Guo H., Zhang M., Zhang J., Li F., Zhong Z., Chen Y., Li Y., Xu P., et al. Combined contribution of increased intestinal permeability and inhibited deglycosylation of ginsenoside Rb1 in the intestinal tract to the enhancement of ginsenoside Rb1 exposure in diabetic rats after oral administration. Drug Metab. Dispos. 2015;43:1702\u20131710. doi: 10.1124/dmd.115.064881.", "ArticleIdList": ["10.1124/dmd.115.064881", "26265741"]}, {"Citation": "Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007;87:1409\u20131439. doi: 10.1152/physrev.00034.2006.", "ArticleIdList": ["10.1152/physrev.00034.2006", "17928588"]}]}], "History": [{"Year": "2018", "Month": "12", "Day": "8"}, {"Year": "2019", "Month": "2", "Day": "22"}, {"Year": "2019", "Month": "2", "Day": "23"}, {"Year": "2019", "Month": "3", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "3", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "3", "Day": "3", "Hour": "6", "Minute": "1"}, {"Year": "2019", "Month": "3", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["30823412", "PMC6468558", "10.3390/cells8030204", "cells8030204"]}}]}